According to a new study, a trial of a new anti-cancer drug interacts with specific genes, which may help refine future treatments. Ceflatonin, a natural product, is being tested as an anti-cancer treatment. Meanwhile, the US company ChemGenex is looking at the effect of the drug on the genes that are activated in cancer. They find that specific genes and cellular pathways are affected by ceflatonin. These experiments have been done in human colon cancer cells and on tumour growth and gene expression in cancer cells grown in mice.
The experiments show how drug dose and administration schedule affect the way people might respond to ceflatonin and maybe other anti-cancer drugs. It points the way to a new way of treating cancer - based upon a knowledge of how gene activity is changed in people who have the disease.